⏬Presentation Slides will be accessible below within 24 hours after the session concludes⏬
Presentation References:
Title: “On Using Machine Learning to Improve Lung Cancer Screening Globally”
Reference: Ardila et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine 25, 954-961 (2019) https://rdcu.be/fjQEp
Title: “Is ctDNA a surrogate endpoint to evaluate targeted therapy efficacy?”
Reference: Andrews et al. ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials. Clin Cancer Res. 2025 Apr 22;31(11):2162–2172. doi: 10.1158/1078-0432.CCR-24-3612
Title: Should we AIM-HIGH?
Reference: “Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial” Lancet Volume 13, Issue 10 p887-896October 2025
Title: The Story of Amivantamab – Underweighting Toxicity and the Patient Experience
References: Mariposa: DOI: 10.1056/NEJMoa2403614; Mariposa 2: 10.1016/j.annonc.2023.10.117